Background Gastrointestinal stromal tumor (GIST) is known for its wide variability in biological behaviors and it is difficult to predict its malignant potential. The aim of this study is to ...

Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available. The ...

Colonic schwannomas and gastrointestinal stromal tumors (GISTs) are rare types of tumors that can occur in the gastrointestinal tract. Schwannomas originate from Schwann cells, which are ...

Gastrointestinal stromal tumors (GISTs) are the most common type of mesenchymal tumors found in the gastrointestinal tract of dogs and are characterized by specific cellular markers. These tumors ...

Among patients with gastrointestinal stromal tumors (GIST), the most common mesenchymal tumor of the GI tract, treatment with bezuclastinib (CGT9486) and Sutent (sunitinib) demonstrated acceptable ...

A multidisciplinary approach is crucial for managing GIST, involving surgical, medical, and potentially targeted therapies. For patients with gastrointestinal stromal tumors with liver metastases, ...

Blueprint Medicines is cutting funding to its clinical-stage CDK2 inhibitor even as the Ayvakit-maker pushes forward with similar preclinical breast cancer-focused therapies.

(RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company, for up to $1.15 billion ...

A clinical-stage biotech founded in 2022 ... Its initial product candidate, IDRX-42, targets gastrointestinal stromal tumor (GIST), a GIT cancer that affects an estimated 4,000–6,000 Americans ...

The Boston-based biotechnology firm is developing therapeutics for the treatment of gastrointestinal stromal tumors ... advance IDRX-42 for patients with GIST given there have been no major ...

UK pharmaceutical giant GSK has confirmed that it has signed an agreement to acquire the privately-held biotechnology company ...